Clinical Study of the Medeon Biodesign XPro™

Inclusion Criteria: * Patient is \> 18 years old * Patient is scheduled for percutaneous BAV, TAVR/TAVI, EVAR, or TEVAR involving access through the femoral artery using an 8-18 Fr introducer sheath * Patient is able to undergo emergent vascular surgery if a complication related to the vascular closure necessitates such surgery * Patient, or authorized representative, signs a written Informed Consent form to participate in the study, prior to any study mandated procedures * Patient is willing and able to complete follow-up Exclusion Criteria: * Prior intra-aortic balloon pump at access site * Patients with severe claudication, iliac or femoral artery diameter stenosis greater than 50% * Common femoral artery lumen diameter is \< 6 mm * Prior target artery closure with any closure device \< 90 days, or closure with manual compression ≤ 30 days prior to index procedure * Prior vascular surgery, vascular graft, or stent in region of access site * Patients receiving glycoprotein IIb/IIIa inhibitors before, during, or after the catheterization procedure * Patients with significant anemia ((Hgb \< 10 g/dL, Hct \< 30%) * Patient with known bleeding disorder including thrombocytopenia (platelet count \< 100,000), thrombasthenia, hemophilia or Von Willebrand's disease * Patients with renal insufficiency (serum creatinine level \> 221µmol/L) or renal transplant * Known allergy to contrast reagent * Inability to tolerate aspirin and/or other anticoagulation treatment * Planned antico…